- Cipla, Guojian launch first biosimilar Enbrel in India
- Ranbaxy ramps up in biosimilars, but must compete in India first
- Kyorin may be among potential Japan partners for Cipla
- Lilly to boost emerging markets play by branding Strides’ anticancers
ONLY 0 DAY LEFT
|Stay close to your market. Renew online now to ensure uninterrupted access to:|
|SCRIP Intelligence's news and expert commentary|
|Market Data and Company Analysis (SCRIP 100, SCRIP Asia 100)|
|The Ask the Analyst Service...and more.|
Please remember to quote your order number and customer number.
You can also renew by calling: +44 (0)20 7017 5540.